Clinical Trial Update: Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy [Phase 2]

View source ↗

Summary

Phase 2 dose-finding trial of CYT003-QbG10 for house dust mite–induced rhinoconjunctivitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis
• Allergic Rhinitis

Drugs mentioned

• CYT003-QbG10

Snippet

Sponsor: Cytos Biotechnology AG | Conditions: Rhinoconjunctivitis, Allergies | Phase 2 | Status: COMPLETED